$CNC

CENTENE CORP

Centene provides managed healthcare products and services primarily for people enrolled in Medicaid, Medicare and commercial health plans. Its customers include individuals and families, state and federal government programs, employers, providers and other health plans. In 2025, Centene operated Medicaid, Medicare, Commercial and Other segments. Its offerings include Medicaid plans; Medicare Advantage, Medicare Prescription Drug Plans and Medicare Supplement; Health Insurance Marketplace and employer coverage; and specialty pharmacy, vision, dental, behavioral health and clinical healthcare services. Centene receives premiums for health coverage, including monthly payments from CMS for Medicare Advantage plans, and pays providers through fee-for-service, capitation and value-based arrangements. Its health plans contract with networks of physicians, hospitals and other providers. Brands include Wellcare for Medicare Advantage and Ambetter Health for Marketplace plans. Centene is headquartered in St. Louis, Missouri.

2
0
4

No SEC Form 4 filings for $CNC in the last 30 days.

See all $CNC insider activity →
Med

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

Bernstein raises Centene stock price target to $90 on Medicaid outlook

Bernstein raised Centene Corp.'s (CNC) price target to $90 from $79, citing strong Q3 results and improved Medicaid prospects. The stock is up 102% in a year. Centene beat EPS estimates and raised full-year guidance, with revenue expected between $196.5B and $200.5B. Analysts highlight undervaluation and growth potential.

11 Medicare Advantage Insurers Sue CMS Over 2027 Star Ratings and Nearly $4 Billion in Payments

Eleven Medicare Advantage insurers, including CVS Health, Elevance Health, and Centene, sued the CMS over 2027 star ratings, claiming nearly $4 billion in potential losses. They argue CMS used unauthorized measures, citing a recent court ruling in Clover Health's favor. Higher ratings affect bonus payments and rebates. CMS is appealing the Clover decision and has not commented on the new lawsuits.

CNC sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning CNC (CENTENE CORP). Coverage has skewed bearish: 2 bullish, 0 neutral, and 4 bearish.

Recent CNC coverage spans market movers, regulation and financial news.

What's driving CNC

AlphAI scores every news story that mentions CNC with an AI model for sentiment and relevance, and aggregates insider trades from CENTENE CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CNC

Score

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

11 Medicare Advantage Insurers Sue CMS Over 2027 Star Ratings and Nearly $4 Billion in Payments

Eleven Medicare Advantage insurers, including CVS Health, Elevance Health, and Centene, sued the CMS over 2027 star ratings, claiming nearly $4 billion in potential losses. They argue CMS used unauthorized measures, citing a recent court ruling in Clover Health's favor. Higher ratings affect bonus payments and rebates. CMS is appealing the Clover decision and has not commented on the new lawsuits.

Positive Medicaid signals, open enrollment trends: Recapping major payers' Q3 results

UnitedHealth Group reported Q3 profit of $4.1B (up from $2.3B YoY) and revenue of $112.7B. CVS Health earned $2.2B (up from a $4B loss YoY) on $108.4B revenue, announcing a split of its pharmacy business. Cigna and Elevance Health each posted $1.4B profit. Centene reduced losses to $71M (from $6.6B YoY) on $50.6B revenue. Humana saw $162M profit (down from $195M) on $41.15B revenue, with positive Medicare enrollment trends.

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

Which Stocks Overreacted To The Midterms?

The article analyzes stock market reactions to the midterm elections, noting that the Dow and S&P 500 rose 3% and 1.6% respectively. Several stocks, including Vertiv (VRT), Centene (CNC), Lockheed (LMT), and GE Vernova (GEV), overreacted to the election results, while others like Vistra (VST) and Oscar (OSCR) had more measured responses.

Centene Surges 10.5% After Truist Securities Reiterates Buy

Centene Corporation's stock surged 10.5% to $74.56 on Wednesday, with a market cap of $37.3B, after Truist Securities, Wells Fargo, and JP Morgan raised their price targets by an average of 7.4%. Truist maintained a Buy rating, while Wells Fargo and JP Morgan adjusted their targets to $75 with Equal-Weight and Neutral ratings, respectively. The average price target is now $77, indicating potential upside.

GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare shares skyrocket, what you need to know

Shares of GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare surged after Democrats regained majorities in Congress, easing drug pricing policy concerns. Analysts expect the biopharmaceutical sector to benefit from reduced regulatory uncertainty. UFP Technologies, up 21.5%, has seen significant volatility and strong performance, including a 51.1% year-to-date gain.

TSX Surges Following U.S. Vote

Canada's TSX index rose 695.16 points (2%) to 36,277.44, while U.S. markets also gained after the U.S. midterm elections. Suncor Energy beat Q3 profit expectations, but shares fell 5%. Canada's trade surplus widened to $5.4B in September. Gold and materials sectors led gains, while energy declined.

Related tickers